Review of renal carcinoma associated with Xp11.2 translocations/TFE3 gene fusions with focus on pathobiological aspect

Naoto Kuroda, Shuji Mikami, Chin Chen Pan, Ronald J. Cohen, Ondrej Hes, Michal Michal, Yoji Nagashima, Yukichi Tanaka, Keiji Inoue, Taro Shuin, Gang Hong Lee

Research output: Contribution to journalArticle

51 Citations (Scopus)

Abstract

The concept of Xp11.2 renal cell carcinoma (RCC) was recently established as a tumor affecting 15% of RCC patients <45 years. Many patients present with advanced stage with frequent lymph node metastases. Histologically, Xp11.2 RCC is characterized by mixed papillary nested/alveolar growth pattern and tumor cells with clear and/or eosinophilic, voluminous cytoplasm. Neoplastic cells show intense nuclear immunoreactivity to TFE3, while focal immunostaining for melanocytic markers, including melanosomeassociated antigen or Melan A in some cases, are also noted. Alpha smooth muscle actin and TFEB are consistently negative. Ultrastructurally, the ASPL-TFE3 RCC variant contains rhomboid crystals in the cytoplasm, similar to that observed in alveolar soft part sarcoma. The fusion of the TFE3 gene with several different genes, including ASPL(17q25), PRCC(1q21), PSF(1q34), NonO (Xq12) and CLTC (17q23) have been identified to date. The behavior of Xp11.2 RCC in children and young adults is considered as indolent even when diagnosed at advanced stage, including lymph node metastasis. However, Xp11.2 RCC in older patients behaves in a more aggressive fashion. Therapy includes nephrectomy with extended lymphadenectomy. There may be a role for new protease inhibitors in advanced inoperable disease. Further research is required to correlate clinical behavior with the expanding genetic spectrum of this tumor, and to establish standard therapy protocols for primary and metastatic lesions.

Original languageEnglish
Pages (from-to)133-140
Number of pages8
JournalHistology and Histopathology
Volume27
Issue number2
Publication statusPublished - 2012 Feb

Fingerprint

Gene Fusion
Renal Cell Carcinoma
Carcinoma
Kidney
Cytoplasm
Alveolar Soft Part Sarcoma
Lymph Nodes
MART-1 Antigen
Neoplasm Metastasis
Neoplasms
Protease Inhibitors
Lymph Node Excision
Nephrectomy
Smooth Muscle
Actins
Young Adult
Antigens
Therapeutics
Growth
Research

Keywords

  • Immunohistochemistry
  • TFE3
  • Xp11.2 RCC

ASJC Scopus subject areas

  • Histology
  • Pathology and Forensic Medicine

Cite this

Review of renal carcinoma associated with Xp11.2 translocations/TFE3 gene fusions with focus on pathobiological aspect. / Kuroda, Naoto; Mikami, Shuji; Pan, Chin Chen; Cohen, Ronald J.; Hes, Ondrej; Michal, Michal; Nagashima, Yoji; Tanaka, Yukichi; Inoue, Keiji; Shuin, Taro; Lee, Gang Hong.

In: Histology and Histopathology, Vol. 27, No. 2, 02.2012, p. 133-140.

Research output: Contribution to journalArticle

Kuroda, N, Mikami, S, Pan, CC, Cohen, RJ, Hes, O, Michal, M, Nagashima, Y, Tanaka, Y, Inoue, K, Shuin, T & Lee, GH 2012, 'Review of renal carcinoma associated with Xp11.2 translocations/TFE3 gene fusions with focus on pathobiological aspect', Histology and Histopathology, vol. 27, no. 2, pp. 133-140.
Kuroda, Naoto ; Mikami, Shuji ; Pan, Chin Chen ; Cohen, Ronald J. ; Hes, Ondrej ; Michal, Michal ; Nagashima, Yoji ; Tanaka, Yukichi ; Inoue, Keiji ; Shuin, Taro ; Lee, Gang Hong. / Review of renal carcinoma associated with Xp11.2 translocations/TFE3 gene fusions with focus on pathobiological aspect. In: Histology and Histopathology. 2012 ; Vol. 27, No. 2. pp. 133-140.
@article{47e585bf484f4332afade52a4ba0538a,
title = "Review of renal carcinoma associated with Xp11.2 translocations/TFE3 gene fusions with focus on pathobiological aspect",
abstract = "The concept of Xp11.2 renal cell carcinoma (RCC) was recently established as a tumor affecting 15{\%} of RCC patients <45 years. Many patients present with advanced stage with frequent lymph node metastases. Histologically, Xp11.2 RCC is characterized by mixed papillary nested/alveolar growth pattern and tumor cells with clear and/or eosinophilic, voluminous cytoplasm. Neoplastic cells show intense nuclear immunoreactivity to TFE3, while focal immunostaining for melanocytic markers, including melanosomeassociated antigen or Melan A in some cases, are also noted. Alpha smooth muscle actin and TFEB are consistently negative. Ultrastructurally, the ASPL-TFE3 RCC variant contains rhomboid crystals in the cytoplasm, similar to that observed in alveolar soft part sarcoma. The fusion of the TFE3 gene with several different genes, including ASPL(17q25), PRCC(1q21), PSF(1q34), NonO (Xq12) and CLTC (17q23) have been identified to date. The behavior of Xp11.2 RCC in children and young adults is considered as indolent even when diagnosed at advanced stage, including lymph node metastasis. However, Xp11.2 RCC in older patients behaves in a more aggressive fashion. Therapy includes nephrectomy with extended lymphadenectomy. There may be a role for new protease inhibitors in advanced inoperable disease. Further research is required to correlate clinical behavior with the expanding genetic spectrum of this tumor, and to establish standard therapy protocols for primary and metastatic lesions.",
keywords = "Immunohistochemistry, TFE3, Xp11.2 RCC",
author = "Naoto Kuroda and Shuji Mikami and Pan, {Chin Chen} and Cohen, {Ronald J.} and Ondrej Hes and Michal Michal and Yoji Nagashima and Yukichi Tanaka and Keiji Inoue and Taro Shuin and Lee, {Gang Hong}",
year = "2012",
month = "2",
language = "English",
volume = "27",
pages = "133--140",
journal = "Histology and Histopathology",
issn = "0213-3911",
publisher = "Histology and Histopathology",
number = "2",

}

TY - JOUR

T1 - Review of renal carcinoma associated with Xp11.2 translocations/TFE3 gene fusions with focus on pathobiological aspect

AU - Kuroda, Naoto

AU - Mikami, Shuji

AU - Pan, Chin Chen

AU - Cohen, Ronald J.

AU - Hes, Ondrej

AU - Michal, Michal

AU - Nagashima, Yoji

AU - Tanaka, Yukichi

AU - Inoue, Keiji

AU - Shuin, Taro

AU - Lee, Gang Hong

PY - 2012/2

Y1 - 2012/2

N2 - The concept of Xp11.2 renal cell carcinoma (RCC) was recently established as a tumor affecting 15% of RCC patients <45 years. Many patients present with advanced stage with frequent lymph node metastases. Histologically, Xp11.2 RCC is characterized by mixed papillary nested/alveolar growth pattern and tumor cells with clear and/or eosinophilic, voluminous cytoplasm. Neoplastic cells show intense nuclear immunoreactivity to TFE3, while focal immunostaining for melanocytic markers, including melanosomeassociated antigen or Melan A in some cases, are also noted. Alpha smooth muscle actin and TFEB are consistently negative. Ultrastructurally, the ASPL-TFE3 RCC variant contains rhomboid crystals in the cytoplasm, similar to that observed in alveolar soft part sarcoma. The fusion of the TFE3 gene with several different genes, including ASPL(17q25), PRCC(1q21), PSF(1q34), NonO (Xq12) and CLTC (17q23) have been identified to date. The behavior of Xp11.2 RCC in children and young adults is considered as indolent even when diagnosed at advanced stage, including lymph node metastasis. However, Xp11.2 RCC in older patients behaves in a more aggressive fashion. Therapy includes nephrectomy with extended lymphadenectomy. There may be a role for new protease inhibitors in advanced inoperable disease. Further research is required to correlate clinical behavior with the expanding genetic spectrum of this tumor, and to establish standard therapy protocols for primary and metastatic lesions.

AB - The concept of Xp11.2 renal cell carcinoma (RCC) was recently established as a tumor affecting 15% of RCC patients <45 years. Many patients present with advanced stage with frequent lymph node metastases. Histologically, Xp11.2 RCC is characterized by mixed papillary nested/alveolar growth pattern and tumor cells with clear and/or eosinophilic, voluminous cytoplasm. Neoplastic cells show intense nuclear immunoreactivity to TFE3, while focal immunostaining for melanocytic markers, including melanosomeassociated antigen or Melan A in some cases, are also noted. Alpha smooth muscle actin and TFEB are consistently negative. Ultrastructurally, the ASPL-TFE3 RCC variant contains rhomboid crystals in the cytoplasm, similar to that observed in alveolar soft part sarcoma. The fusion of the TFE3 gene with several different genes, including ASPL(17q25), PRCC(1q21), PSF(1q34), NonO (Xq12) and CLTC (17q23) have been identified to date. The behavior of Xp11.2 RCC in children and young adults is considered as indolent even when diagnosed at advanced stage, including lymph node metastasis. However, Xp11.2 RCC in older patients behaves in a more aggressive fashion. Therapy includes nephrectomy with extended lymphadenectomy. There may be a role for new protease inhibitors in advanced inoperable disease. Further research is required to correlate clinical behavior with the expanding genetic spectrum of this tumor, and to establish standard therapy protocols for primary and metastatic lesions.

KW - Immunohistochemistry

KW - TFE3

KW - Xp11.2 RCC

UR - http://www.scopus.com/inward/record.url?scp=84863407430&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84863407430&partnerID=8YFLogxK

M3 - Article

C2 - 22207547

AN - SCOPUS:84863407430

VL - 27

SP - 133

EP - 140

JO - Histology and Histopathology

JF - Histology and Histopathology

SN - 0213-3911

IS - 2

ER -